Dmitriy Minond

Dmitriy Minond, Ph.D., is a Professor at the Barry and Judy Silverman College of Pharmacy, Rumbaugh-Goodwin Cancer Research Department, Nova Southeastern University. A biochemist specializing in drug discovery, his work bridges cancer biology and neurodegenerative diseases. He earned his Ph.D. in Chemistry and Biochemistry from Florida Atlantic University, followed by postdoctoral studies at The Scripps Research Institute, and held academic roles at Torrey Pines Institute for Molecular Studies and Harrison School of Pharmacy at Auburn University.

• Key Research Areas: Drug discovery for melanoma, Alzheimer's disease, and protease-related pathologies.
• Expertise: Metalloprotease inhibition, glycosylation effects, high-throughput screening assays, and xenograft models.
• Professional Affiliations: American Association for Cancer Research, International Proteolysis Society, American Peptide Society.

His research focuses on developing exosite-targeting inhibitors for ADAM proteases, exploring lipid metabolism in melanoma, and elucidating glycosylation's role in neurodegenerative diseases. He has authored over 50 publications, contributed to book chapters, and served as an editor and reviewer for scientific journals. Dr. Minond has secured grants from the Florida Biomedical Council and National Cancer Institute to advance his work.

Recent publications highlight his innovations in tissue-engineered microspheres for drug screening, mechanosensing in periodontitis, and the interplay between spliceosomal proteins and melanoma immune signaling. His studies on APP glycosylation in Alzheimer's disease underscore his integrative approach to targeting proteases in diverse pathologies.

• Scientific Awards & Grants
  • Florida Biomedical Council Grant
  • National Cancer Institute Grant

Dr. Minond's contributions to drug development include novel anti-melanoma compounds with in vivo efficacy, mechanistic insights into metalloprotease activity, and advances in high-throughput screening technologies. His work on autophagy modulation and targeted drug delivery systems continues to push therapeutic boundaries.